Cytomegalovirus infection

This phase 1 trial tests a higher dose of the experimental HIV vaccine VIR-1388 in about 12 adults aged 18 to 55 who already carry cytomegalovirus (CMV). The vaccine uses a weakened CMV virus to deliver HIV proteins, aiming to trigger a strong immune response. Participants receiv…

This study tests whether oral valganciclovir or ganciclovir eye drops can reduce the virus causing eye inflammation and prevent flare-ups. About 117 adults with CMV anterior uveitis will receive either antiviral treatment or placebo for 7 days, then some continue for 12 months. T…

This study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infe…

This study tests whether adjusting the dose of anti-rejection drugs can help control CMV infection in organ transplant recipients. About 100 adults who have had a kidney, liver, heart, lung, or pancreas transplant and now have a CMV infection will take part. Researchers will moni…

This early-stage trial tests whether treating a donor kidney with a drug called SYN002 before transplant can safely reduce the risk of passing cytomegalovirus (CMV) to the recipient. About 12 adults waiting for a kidney transplant will receive a treated organ. The main goal is to…

This study compares a 4-month course of antiviral medication (ganciclovir or valganciclovir) against the standard 6-month course for babies born with moderate-to-severe congenital CMV infection. The goal is to see if the shorter treatment works just as well at preventing long-ter…

This study tests a scoring system that uses immune system recovery to decide how long patients should take antiviral medicine after a stem cell transplant. The goal is to prevent a common virus called CMV from causing infection. About 1,114 transplant recipients will take part to…

This study tests whether valganciclovir, a drug that stops CMV from multiplying, can safely lower CMV levels in the blood of people with advanced HIV. About 130 adults and adolescents with very weak immune systems will be randomly assigned to take either valganciclovir or a place…

This study tests two different drug combinations to prevent cytomegalovirus (CMV) infection in kidney transplant patients who are at high risk. Thirty adults who are CMV-positive before transplant will receive either tacrolimus plus mTOR inhibitors with early antiviral treatment,…

This study will test a new blood test that looks for tiny molecules called miRNAs to detect HCMV infection earlier in people who have received a stem cell transplant. The standard DNA test can miss early signs, so researchers hope this new method will give doctors a head start. A…

This study investigates whether the drug letermovir can prevent cytomegalovirus (CMV) infection in adults who have received a kidney or liver transplant and have been previously exposed to CMV. Participants take one letermovir tablet daily for 84 days after transplant. The goal i…

This study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it ta…

This study looks back at medical records of 200 adults who received organ transplants in Argentina between 2017 and 2024 to see how often cytomegalovirus (CMV) infections become resistant to standard antiviral drugs. Researchers will identify cases where the virus does not respon…

This study will follow 1000 kidney transplant patients for one year to see if monthly blood tests for certain viruses (CMV, BK, and TTV) can help predict and prevent serious infections and kidney damage. The goal is to learn how the body's immune system and virus levels relate to…

This study looks at whether measuring two new viral markers (CMV-RNA and TTV-DNA) in the blood can give a clearer picture of CMV infection in patients who have had a stem cell transplant and are taking the drug letermovir to prevent CMV. Researchers will track 290 adult transplan…

This study follows 123 stem cell transplant patients to see if measuring their immune response to CMV after stopping a preventive drug (letermovir) can predict late infections. Participants will have regular blood tests up to 200 days after transplant. The goal is to learn whethe…

This study looks at how CMV (a common virus) changes the immune system in people who have had a kidney transplant. Researchers will take blood samples from 60 patients to compare immune responses in those with and without CMV infection. The goal is to understand why CMV may incre…